These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 20006922)

  • 101. Renal effects of targeted anticancer therapies.
    Porta C; Cosmai L; Gallieni M; Pedrazzoli P; Malberti F
    Nat Rev Nephrol; 2015 Jun; 11(6):354-70. PubMed ID: 25734768
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Incidence and risk of proteinuria with aflibercept in cancer patients: a meta-analysis.
    Peng L; Zhao Q; Ye X; Zhou Y; Hu D; Zheng S
    PLoS One; 2014; 9(11):e111839. PubMed ID: 25365378
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway.
    Hamnvik OP; Choueiri TK; Turchin A; McKay RR; Goyal L; Davis M; Kaymakcalan MD; Williams JS
    Cancer; 2015 Jan; 121(2):311-9. PubMed ID: 25236375
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Anti-VEGF Cancer Therapy in Nephrology Practice.
    Izzedine H
    Int J Nephrol; 2014; 2014():143426. PubMed ID: 25210627
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Inhibition of the VEGF signalling pathway and glomerular disorders.
    Ollero M; Sahali D
    Nephrol Dial Transplant; 2015 Sep; 30(9):1449-55. PubMed ID: 25480873
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Incidence and relevance of proteinuria in bevacizumab-treated patients: pooled analysis from randomized controlled trials.
    Lafayette RA; McCall B; Li N; Chu L; Werner P; Das A; Glassock R
    Am J Nephrol; 2014; 40(1):75-83. PubMed ID: 25059491
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Impact of preexisting proteinuria on the development of regorafenib-induced problematic proteinuria in real-world metastatic colorectal cancer treatment.
    Saito Y; Takekuma Y; Komatsu Y; Sugawara M
    Sci Rep; 2024 Mar; 14(1):5153. PubMed ID: 38431746
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Machine learning application identifies plasma markers for proteinuria in metastatic colorectal cancer patients treated with Bevacizumab.
    Yu Z; Xu H; Feng M; Chen L
    Cancer Chemother Pharmacol; 2024 Jun; 93(6):587-593. PubMed ID: 38402561
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Safety of bevacizumab and olaparib as frontline maintenance therapy in advanced ovarian cancer: expert review for clinical practice.
    Romero I; Guerra E; Madariaga A; Manso L
    Front Oncol; 2023; 13():1304303. PubMed ID: 38348122
    [TBL] [Abstract][Full Text] [Related]  

  • 110. A Case of Anti-vascular Endothelial Growth Factor Therapy-Related Nephrotic Syndrome With Marked Intraglomerular Macrophage Infiltration.
    Obara S; Inoue T; Watanabe Y; Hamaguchi T; Ikezawa T; Amano H; Ishizawa K; Okada H
    Cureus; 2023 Dec; 15(12):e50496. PubMed ID: 38222188
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Administration of Bevacizumab and the Risk of Chronic Kidney Disease Development in Taiwan Residents: A Population-Based Retrospective Cohort Study.
    Lye LF; Chou RH; Wu TK; Chuang WL; Tsai SC; Lin HJ; Tsai FJ; Chang KH
    Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203509
    [TBL] [Abstract][Full Text] [Related]  

  • 112. The renal damage and mechanisms relevant to antitumoral drugs.
    Tang J; Yang N; Pan S; Ren P; Chen M; Jin J; He Q; Zeng Y
    Front Oncol; 2023; 13():1331671. PubMed ID: 38148845
    [TBL] [Abstract][Full Text] [Related]  

  • 113. The importance of early-stage blood pressure control in thyroid cancer patients treated with lenvatinib from the perspective of dose intensity.
    Masaki C; Shioya J; Sugino K; Terasawa Y; Yokotsuka S; Nakata M; Kitagawa W; Ito K
    Support Care Cancer; 2023 Nov; 31(12):729. PubMed ID: 38017341
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Chapter 3: Management of kidney injury caused by cancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022.
    Ando Y; Nishiyama H; Shimodaira H; Takano N; Sakaida E; Matsumoto K; Nakanishi K; Sakai H; Tsukamoto S; Komine K; Yasuda Y; Kato T; Fujiwara Y; Koyama T; Kitamura H; Kuwabara T; Yonezawa A; Okumura Y; Yakushijin K; Nozawa K; Goto H; Matsubara T; Hoshino J; Yanagita M;
    Int J Clin Oncol; 2023 Oct; 28(10):1315-1332. PubMed ID: 37453935
    [TBL] [Abstract][Full Text] [Related]  

  • 115. The Association of Intravitreal Anti-VEGF Injections With Kidney Function in Diabetic Retinopathy.
    Bunge CC; Dalal PJ; Gray E; Culler K; Brown JJ; Quaggin SE; Srivastava A; Gill MK
    Ophthalmol Sci; 2023 Dec; 3(4):100326. PubMed ID: 37449049
    [TBL] [Abstract][Full Text] [Related]  

  • 116. Renal Implications of Long-Term Systemic Bevacizumab for Recurrent Respiratory Papillomatosis.
    Robinson CH; Hart-Matyas M; Morgenstern DA; Noone D; Campisi P
    Ann Otol Rhinol Laryngol; 2024 Jan; 133(1):119-123. PubMed ID: 37439024
    [TBL] [Abstract][Full Text] [Related]  

  • 117. Comparative analysis of mortality and progression to end-stage renal disease between surgically induced and medical chronic kidney disease: A study using the National Health Insurance customized database.
    Jung G; Park S; Kim H; Lee J; Jeong CW
    Investig Clin Urol; 2023 Jul; 64(4):338-345. PubMed ID: 37417558
    [TBL] [Abstract][Full Text] [Related]  

  • 118. Chapter 1: Evaluation of kidney function in patients undergoing anticancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022.
    Muto S; Matsubara T; Inoue T; Kitamura H; Yamamoto K; Ishii T; Yazawa M; Yamamoto R; Okada N; Mori K; Yamada H; Kuwabara T; Yonezawa A; Fujimaru T; Kawano H; Yokoi H; Doi K; Hoshino J; Yanagita M
    Int J Clin Oncol; 2023 Oct; 28(10):1259-1297. PubMed ID: 37382749
    [TBL] [Abstract][Full Text] [Related]  

  • 119. Drug-Induced Podocytopathies: Report of Four Cases and Review of the Literature.
    Athanasopoulou D; Lionaki S; Skalioti C; Liapis G; Vlachoyiannopoulos P; Boletis I
    Life (Basel); 2023 May; 13(6):. PubMed ID: 37374047
    [TBL] [Abstract][Full Text] [Related]  

  • 120. The Inflammatory Profile Orchestrated by Inducible Nitric Oxide Synthase in Systemic Lupus Erythematosus.
    Ene CD; Nicolae I
    J Pers Med; 2023 May; 13(6):. PubMed ID: 37373923
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.